Quarterly report pursuant to Section 13 or 15(d)

Acquisitions - Narrative (Details)

v3.23.1
Acquisitions - Narrative (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Jul. 01, 2022
Mar. 31, 2023
Mar. 31, 2023
Payments to Acquire Businesses, Net of Cash Acquired, Total     $ 101,184
Namocell Inc      
Business Combination, Consideration Transferred, Total     111,784
Maximum contingent consideration $ 25,000 $ 25,000 25,000
Payments to Acquire Businesses, Net of Cash Acquired, Total $ 101,200   101,184
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual   1,100 5,700
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual   (2,700) (5,800)
Namocell Inc | Developed Technology Rights [Member]      
Finite-Lived Intangible Asset, Useful Life (Year) 13 years    
Namocell Inc | Customer Relationships [Member]      
Finite-Lived Intangible Asset, Useful Life (Year) 4 years    
Namocell Inc | Trade Names [Member]      
Finite-Lived Intangible Asset, Useful Life (Year) 3 years    
Namocell Inc | Noncompete Agreements [Member]      
Finite-Lived Intangible Asset, Useful Life (Year) 3 years    
Acquisition of Asuragen, Inc. [Member]      
Maximum contingent consideration   $ 105,000 $ 105,000